Cardinal Health (NYSE:CAH - Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, January 30th. Analysts expect Cardinal Health to post earnings of $1.74 per share and revenue of $53,904,600.00 billion for the quarter. Cardinal Health has set its FY25 guidance at $7.75-7.90 EPS and its FY 2025 guidance at 7.750-7.900 EPS.Persons interested in participating in the company's earnings conference call can do so using this link.
Cardinal Health (NYSE:CAH - Get Free Report) last issued its quarterly earnings data on Friday, November 1st. The company reported $1.88 earnings per share for the quarter, beating analysts' consensus estimates of $1.62 by $0.26. The business had revenue of $52.28 billion for the quarter, compared to the consensus estimate of $50.90 billion. Cardinal Health had a negative return on equity of 56.56% and a net margin of 0.56%. The firm's revenue was down 4.3% compared to the same quarter last year. During the same period last year, the business earned $1.73 EPS. On average, analysts expect Cardinal Health to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.
Shares of Cardinal Health stock opened at $128.73 on Thursday. Cardinal Health has a 12-month low of $93.17 and a 12-month high of $129.36. The stock has a 50 day moving average price of $120.99 and a two-hundred day moving average price of $112.58. The stock has a market capitalization of $31.15 billion, a P/E ratio of 25.04, a PEG ratio of 1.54 and a beta of 0.63.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Thursday, January 2nd were issued a dividend of $0.5056 per share. This represents a $2.02 annualized dividend and a dividend yield of 1.57%. The ex-dividend date was Thursday, January 2nd. Cardinal Health's dividend payout ratio is currently 39.30%.
Several research analysts recently commented on CAH shares. UBS Group boosted their target price on shares of Cardinal Health from $134.00 to $139.00 and gave the stock a "buy" rating in a research report on Monday, November 4th. Morgan Stanley boosted their price objective on Cardinal Health from $127.00 to $136.00 and gave the stock an "overweight" rating in a research report on Tuesday, December 17th. TD Cowen raised Cardinal Health from a "hold" rating to a "buy" rating and raised their target price for the company from $130.00 to $144.00 in a report on Wednesday, January 8th. Barclays lifted their price target on Cardinal Health from $117.00 to $133.00 and gave the stock an "overweight" rating in a research report on Monday, November 4th. Finally, Wells Fargo & Company raised Cardinal Health from an "underweight" rating to an "equal weight" rating and increased their price objective for the company from $101.00 to $127.00 in a research report on Friday, December 13th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Cardinal Health currently has an average rating of "Moderate Buy" and an average target price of $133.29.
Read Our Latest Report on Cardinal Health
Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cardinal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.
While Cardinal Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.